Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial

Sara Nagy (sara.nagy@ukbb.ch)  
UKBB  https://orcid.org/0000-0002-3508-860X

Patricia Hafner  
University Children’s Hospital Basel

Simone Schmidt  
University Children’s Hospital Basel

Daniela Rubino-Nacht  
University Children’s Hospital Basel

Sabine Schädelin  
Clinical Trial Unit, University of Basel

Oliver Bieri  
Department of Radiology, University Hospital Basel

Dirk Fischer  
University Children’s Hospital Basel

Study protocol

Keywords: Duchenne muscular dystrophy, tamoxifen, motor function measure, 6-minute walk test, quantitative muscle MRI, randomized placebo controlled trial

Posted Date: June 5th, 2019

DOI: https://doi.org/10.21203/rs.2.10085/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on November 21st, 2019. See the published version at https://doi.org/10.1186/s13063-019-3740-6.
Abstract

BACKGROUND Duchenne muscular dystrophy (DMD) is an inherited neuromuscular disorder of childhood with a devastating disease course. Several targeted gene therapies and molecular approaches have been or are currently tested in clinical trials; however, a causative therapy is still not available and best supportive care is limited to oral glucocorticoids with numerous long-term side effects. Tamoxifen is a selective estrogen receptor regulator, and shows besides its antitumor activity also antioxidant actions and regulatory roles in the calcium homeostasis. In a mouse model of DMD, oral tamoxifen significantly improved muscle strength and reduced muscle fatigue. This multicenter, randomized, double-blind, placebo controlled phase 3 trial aims to demonstrate safety and efficacy of tamoxifen over placebo in pediatric patients with DMD. After completion of the double-blind phase, an open label extension of the study will be offered to all participants. METHODS/DESIGN At least 71 ambulant and up to 20 non-ambulant patients with DMD are planned to be enrolled at multiple European sites. Patients will be randomly assigned to receive either tamoxifen 20mg or placebo daily over 48 weeks. In the open-label extension phase, all patients will be offered to receive tamoxifen for further 48 weeks. The primary endpoint of the double-blind phase is defined as the change of the D1 domain of the motor function measure in ambulant patients or a change of the D2 domain in non-ambulant patients under tamoxifen compared to placebo. Secondary outcome measures include change in timed function tests, quantitative muscle testing, and quantitative MRI of thigh muscles. Laboratory analyses including biomarkers of tamoxifen metabolism and muscle dystrophy will also be assessed. DISCUSSION The aim of the study is to investigate whether tamoxifen can reduce disease progression in ambulant and non-ambulant DMD patients over 48 weeks. Motor function measure comprises the primary endpoint, whereas further clinical and radiological assessments and laboratory biomarkers are performed to provide more data on safety and efficacy. An adjacent open label extension phase is planned to test if earlier initiation of the treatment with tamoxifen (verum arm of double blind phase) compared to a delayed start can reduce disease progression more efficiently.

Background

Duchenne muscular dystrophy (DMD) is the most common neuromuscular disorder in childhood with an X-linked inheritance and an incidence of up to 1:5000 males\(^1\)-\(^2\). The severe and progressive weakness of skeletal muscles leads to loss of ambulation in 22 to 56% of the cases, whereas the concomitant impairment of cardiac and respiratory muscles accounts for an early mortality\(^2\).

The clinical and pathological phenotype of DMD is caused by mutations in the dystrophin gene, which results in the total loss of dystrophin protein expression in the muscle cells\(^3\). Dystrophin has a major role in sarcolemmal stabilization by linking the internal actin cytoskeleton to the extracellular matrix. The protein is part of the dystrophin-associated protein complex (DAPC) including numerous integral and peripheral membrane proteins\(^4\). The lack of dystrophin leads to destabilization of DAPC and to increased vulnerability and leakage of the cell membrane\(^5\). There is also growing evidence that DAPC has a role in
intracellular signaling pathways due to its association to several kinases, phosphatases, ion channels, receptors and transporters, which pathways seem to have significance in the disease pathogenesis. If dystrophin is missing, its downstream processing is dysregulated, leading to increased calcium ($\text{Ca}^{2+}$) influx, oxidative stress and mitochondrial dysfunction. Increased cytosolic $\text{Ca}^{2+}$ level is a result of many dysfunctional pathways involving store-operated channels, stretch-activated channels, the sarcolemmal $\text{Ca}^{2+}$ pump and calpains. Increased intracellular $\text{Ca}^{2+}$ levels were shown in mdx mice and also in muscle biopsies from DMD patients, implicating $\text{Ca}^{2+}$ as a main driver of the pathology responsible for apoptosis and necrosis. It has even been shown, that increased $\text{Ca}^{2+}$ influx alone is sufficient to induce muscular dystrophy through transient receptor potential canonical 3 (TRPC3)-mediated pathways.

Several targeted gene therapies and molecular approaches counteracting the dysfunctional intracellular pathways have been tested in mdx animal models and many are currently investigated in clinical trials. However, the proof of principle for DMD patients has yet to be established. Tamoxifen is a selective estrogen receptor regulator and its use is well established in patients with breast cancer. Tamoxifen acts as an agonist or antagonist of estrogen in a tissue-dependent manner. Advantages of tamoxifen include its antioxidant actions and regulatory roles in the calcium homeostasis. According to yet unpublished data, tamoxifen leads to an elevated level of pro-inflammatory cytokines and growth factors involved in muscle regeneration and fibrosis (transforming growth factor beta (TGF-β), Insulin-like growth factor 1 (IGF I), osteopontin) and to an increased capacity of muscle-purified mitochondria to buffer cytosolic calcium. Tamoxifen is able to prevent bone loss and has been shown to increase the height of short boys by decreasing the rate of bone maturation. In a mouse model of DMD, oral tamoxifen stabilized the membrane of myofibres, significantly improved muscle strength, reduced muscle fatigue, and slowed phenotype. Further, tamoxifen could reduce fibrosis of the heart muscle and diaphragm by about 50%. The effectiveness of tamoxifen has recently been shown in another fatal congenital muscular disorder. In a mouse model of myotubular myopathy, tamoxifen could improve force, decrease disease progression and prolong survival.

Preclinical and clinical data of tamoxifen in muscular dystrophy are promising and the findings suggest its usage also in patients with DMD. According to unpublished results of an open label trial (ClinicalTrials.gov identifier: NCT02835079), tamoxifen has beneficial effects in a daily dose of 20mg. Patients with DMD taking tamoxifen remained stable over an observation time of 12 month and showed a good tolerance of the medication without any treatment-related serious adverse events. Tamoxifen has also been previously tested in the pediatric population for low-and high-grade glioma, desmoid-tumor, pubertal gynecomastia and short height. Treatment with tamoxifen was well tolerated in each study, even when used at higher doses.

The purpose of this study is to evaluate the effect of tamoxifen on muscle function and muscle force compared to placebo in ambulant and non-ambulant children with DMD. Furthermore, regular pharmacokinetic evaluation of tamoxifen plasma levels and metabolites, and detailed analysis of
biomarkers of muscle degeneration, muscle necrosis (e.g. creatine kinase (CK), alkaline phosphatase (AP)) and muscle dystrophy (e.g. tumor necrosis factor (TNF), TGF-β, interleukin 1-beta (IL1-β), interleukin 6 (IL6)) could provide a better understanding of tamoxifen's mode of action. In the current lack of an effective and safe long-term treatment for DMD patients, tamoxifen could be a milestone in improving clinical outcome while providing good safety and tolerability.

**Methods**

**Study design**

This is an investigator-initiated, multicenter, randomized, double-blind, placebo controlled phase 3 efficacy and safety trial in patients with DMD. This part of the study is conducted over 48 weeks. The two treatment arms include tamoxifen (verum) and placebo (control). We plan to enroll at least 71 ambulant patients aged between 6.5 and 12 years (group A) and 16 – 20 non-ambulant patients aged between 10 and 16 years (group B) at multiple European sites (Belgium, France, Germany, Holland, Spain, Switzerland, Turkey, United Kingdom). After completion of the open label phase, all patients will be offered to take part in an open label extension (OLE) trial of the main study. In this part, all patients will receive tamoxifen for 48 weeks.

The trial was approved by the local ethics committee (Ethics Committee of Both Basel cantons, 2017-01708), the National Swiss Drug Agency (Swissmedic, 2018DR3068) the European Union Drug Regulating Authorities Clinical Trials and (EudraCT 2017-004554-42), the European Union Drug Regulating Authorities Pharmacovigilance (EudraVigilance). The study was registered at ClinicalTrials.gov (NCT03354039) and at the Swiss National Clinical Trials Portal (SNCTP000002387) prior recruitment. The (SPIRIT) flow chart showing the main study design is seen in Fig. 1, while Fig. 2 represents the study design of the OLE phase. The Recommendations for Interventional Trials (SPIRIT) Checklist on which the study protocol is based is presented as Additional file 1.

**Inclusion criteria**

Only male patients with a molecular diagnosis of DMD are included in the study. Ambulant patients in group A must fulfill the following criteria at screening: 6.5 to 12 years of age, weight > 20kg, stable treatment with glucocorticoids > 6 months, ability to walk at least 350 meters without assistance in 6-minute walk test (6MWT) and a D1 domain of the motor function measure (MFM) > 40%. Non-ambulant patients in group B must be between 10 and 16 years of age at time of screening, be off glucocorticoids for > 6 months, and have no ability to walk more than 10 meters. Patients taking ataluren should be under a stable ataluren treatment for at least 3 months or be off ataluren treatment for at least 3 months before screening. For participation in the OLE trial, preceding completion of the main study is mandatory.
Exclusion criteria

Patients fulfilling the following criteria are excluded from the study: females, allergy to tamoxifen, use of tamoxifen or testosterone within the last 3 months, known or suspected malignancy, clinically relevant disease with limitation of renal, liver or heart function, injury impacting functional testing, planned or expected spinal fusion surgery during the study period, previous spinal fusion surgery within the last 6 months, galactosemia, congenital lack of lactase, glucose-galactose malabsorption. Patients taking CYP2D6 inhibitors, CYP3A4 inducers, platelet aggregation inhibitors, coumarin-type anti-coagulants, or drugs metabolized by CYP2C9 must also be excluded. Further, patients with certain eye disorders (cataract, retinopathy, optic neuropathy, alteration of the cornea) and those with laboratory abnormalities such as anemia, thrombocytopenia, leukopenia, neutropenia or agranulocytosis are not allowed to be included either. Patients taking part in the trial should not concomitantly participate in any other interventional trial and up to 3 months prior to screening.

Randomization and blinding

Patients who meet the study admission criteria and do not fulfill any exclusion criteria are enrolled and randomly assigned to either the active treatment or the control treatment with a treatment allocation of 1:1. The study is double-blind, therefore, all clinical investigators and all patients and their caregivers will remain blinded throughout the trial. Patients who withdraw from the study will not be replaced. At the end of the main part, all patients will be asked to join the OLE trial, receiving active treatment only. Participants can leave the study at any time for any reason.

Intervention

All patients who undergo randomization will receive an oral drug once daily: either tamoxifen at a dose of 20mg (verum) or placebo (control). The placebo medication will have the same texture, taste and color as the interventional drug, but without any active ingredients. Both the interventional and the control drug are manufactured by Hexal AG, Industriestrasse 25, 83607 Holzkirchen, Germany. Tamoxifen tablets will be protected from light and moisture.

The intervention period lasts 48 weeks with an end of study visit at week 60. The study medication is taken on top of standard care with glucocorticoids in group A, if treatment with steroids has been stable over the last 6 months prior screening (dose adaptations according to weight change are allowed). After completing the main study, an OLE is performed, where all patients will be offered to take tamoxifen.

Study procedure
Patients enrolled in the study attend a screening visit 4 weeks prior to baseline. Study visits take place every 12 weeks during the intervention period of 48 weeks. The double-blind phase of the study ends with a visit at week 48, respectively with a follow-up visit at week 60 for patients not participating in the extension phase.

At screening (visit 0), patients and their caregivers receive detailed information about preclinical data, study procedure and possible benefits and risks of the trial. After signing the informed consent form, inclusion and exclusion criteria will be verified. Patients/caregivers are asked to sign a separate optional informed consent form for collection of data for further genetic and biomarker analysis. Patient fulfilling the criteria will be enrolled and undergo the following investigations: physical examination, vital signs, blood draw for safety laboratory tests, and physiotherapy assessment including MFM, North Star Ambulatory Assessment (NSAA), proximal upper limb function (PUL), timed function tests (TFT), 6MWT, 10-meters walk/run test (10MWT), time to rise from floor and quantitative muscle testing (QMT) using grip force. An ophthalmological examination including visual acuity and slit lamp is performed either at screening or in the time period between screening and baseline.

The baseline visit (visit 1) takes place no longer than 4 weeks after screening. During this visit, fulfillment of the inclusion/exclusion criteria are reassessed and qualified patients randomized to receive the study medication (verum or placebo). During this visit, the following procedures are performed: physical examination, vital signs, Tanner staging (assessment of the external primary and secondary sex characteristics), blood draw, adverse events, calculation of Wells score (risk estimation for deep vein thrombosis), complete physiotherapy assessment as described above, quantitative muscle (qMRI) of the thigh measuring the mean fat fraction (FF) and T2 relaxation time (T2), ophthalmological examination, patient reported outcome measures using the Personal-Adjustment and Role Skills-Scale (PARS-III) and Raven’s Coloured Progressive Matrices (RCPM). In selected sites, also an X-ray bone age determination and Dual x-ray absorptiometry (DEXA) will be performed during this visit.

Six weeks after baseline, patients receive a phone call to capture any early adverse events and to assess the Wells score.

At weeks 12 and 36 (visits 2 and 4, respectively), the following procedures will be performed: physical examination, vital signs, adverse events, blood draw, Wells score, and complete physiotherapy assessment.

At weeks 24 and 48 (visits 3 and 5, respectively), the following procedures will take place: physical examination, vital signs, Tanner staging, blood draw, Wells score, complete physiotherapy assessment, qMRI, ophthalmological examination, and PARS-III. At week 48, RCPM will be repeated and in selected sites, X-ray bone age determination and DEXA performed. For patients not participating in the OLE phase, a follow-up visit takes place at week 60 (visit 6) and includes the followings: physical examination, vital signs, adverse events, blood draw, and Wells score.
Informed consent for the OLE phase will be given to all patients/caregivers already at screening, but withdrawal from the extension phase is possible at any time throughout the study. Patients confirming their participation in the OLE phase will be re-checked for the inclusion and exclusion criteria at week 48 (1OLE). All patients will receive a phone call six weeks after starting the OLE and are asked for early adverse events and to evaluate the Wells score. Study visits will be performed every 12 weeks and include the same assessments as the main study. At weeks 60 (2OLE) and 84 (4OLE), the following procedures will be performed: physical examination, vital signs, adverse events, blood draw, Wells score, and complete physiotherapy assessment. At weeks 72 (3OLE) and 96 (5OLE), physical examination, vital signs, Tanner staging, blood draw, Wells score, complete physiotherapy assessment, qMRI, ophthalmological examination, and PARS-III will take place. During 5OLE, additionally RCPM will be repeated and in selected sites X-ray bone age determination and DEXA performed. For all patients of the OLE, a follow-up visit at week 102 (6OLE) is planned including physical examination, vital signs, adverse events, blood draw and Wells score. Table 1 and Table 2 show the detailed schedule of the placebo-controlled, double-blind (RCT) and the OLE phase of the study, respectively.

Quality assurance

This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, the Good Clinical Practice from the International Council for Harmonization (ICH-GCP) and with all national legal and regulatory requirements. In order to achieve this, the members of the study team are required to hold an updated certification in GCP. All physiotherapists will be trained and certified for motor function measure. To control adherence to the intervention, a qualified person of the study team will check the number of dispensed/taken medication and complete a study specific drug accountability form at each visit. A distributor (Thermo Fisher Scientific, Allschwil, Switzerland), who is not involved in the study, will pack, label and dispense the medication according to the randomization procedure in order to prevent unblinding of the investigators.

Safety assessments

Adverse events will be monitored throughout the study. At every visit, patients and their caregivers will be asked about adverse events. Measurement of vital parameters (blood pressure, heart rate, ECG), physical examination and assessment of the Wells score will be performed. Safety laboratory measurements include full blood count, CK, AP, gamma GT, total bilirubin, urea, creatinine, electrolytes, and triglyceride. Further laboratory assessments (such as luteinising hormone (LH), follicle stimulating hormone (FSH), testosterone, sexual hormone binding globulin (SHBG), alpha-fetoprotein (AFP), plasma levels of tamoxifen and its metabolites, biomarkers) will be performed at defined time points during the study (Fig. 1, Fig. 2). Visual acuity and split-lamp examinations performed by an ophthalmologist or optician and Tanner staging are done at three study visits both during the intervention and the OLE phase. RCPM will
be performed at two time points of both the intervention and the OLE phase. X-ray bone age determination and DEXA scan are planned only in selected sites. A safety follow-up will take place for patients with early study termination and include the followings: assessment of adverse events, vital parameters, physical examination, safety blood test and biomarkers, Tanner staging, Wells score, ophthalmological examination, RCPM, physiotherapeutic evaluation and DEXA scan at selected sites.

The study medication must be immediately discontinued in the following cases: decrease in visual acuity of more than 30% compared to baseline, cataract or optic nerve involvement or any other significant novel eye disease, thromboembolic event, newly diagnosed malignancy, or any other severe drug related adverse events or serious adverse events. Also, laboratory abnormalities including platelet count < 75 \times 10^9/l, absolute neutrophil count < 1 \times 10^9/l and serum Ca^{2+} > 2.6 \text{ mmol/l} must lead to treatment discontinuation. Furthermore, withdrawal of consent, patient’s noncompliance, logistical reasons or inability to attend study visits can also lead to early termination of the study. Finally, in case of negative (non-significant) differences of the primary endpoint after analysis of the RCT phase, the OLE phase will be finished and the active treatment stopped immediately in all study patients.

All serious adverse events must be reported to the Sponsor-Investigator of the study within 24 hours after an investigator become aware of this event. In case of life-threatening serious adverse events or those resulting in death, also the local national Ethics Committee must be informed within 7 days. Patients with adverse events will be followed up by the investigator up to 30 days after the last visit.

Both, patients and their partners of child-bearing potential must employ a reliable method of birth control during the study and for further 90 days after the intake of the study drug. Special attention must be paid to sun protection throughout the trial and up to at least 12 weeks after the trial ends. In case of problems and safety concerns that cannot be solved with on-going blinded treatment, the participant’s allocated intervention will be revealed. Unblinding can be performed by the investigators using the randomizer.at tool. Any important protocol modifications will be directly communicated to all relevant parties. Under emergency circumstances, deviations from the protocol to protect the rights, safety and well-being of human subjects may proceed without prior approval of the sponsor and the ethics committee. Deviations must be documented and reported to the sponsor and the ethics committee as soon as possible.

**Efficacy outcome measures**

Outcomes and endpoints are the same for both the placebo controlled and open label extension phases of the trial.

**Primary efficacy outcome measures**
Change of D1 domain of motor function under tamoxifen compared to placebo in ambulant patients

In group A including only ambulant patients, the primary efficacy outcome is the change of motor function measured by the motor function measure (MFM). MFM is a commonly used assessment in patients with Duchenne muscular dystrophy that has been validated in Lyon, France\textsuperscript{29-31}. The test measures all dimensions of the motor function by evaluating standing and transfer (D1 domain), axial and proximal- (D2 domain), and distal motor function (D3 domain). The reliability of the MFM has been examined in several studies. It is described to be sensitive to treatment response\textsuperscript{32}, and to disease progression even within as short periods as 3 months\textsuperscript{33-34}. The D1 domain of the MFM, assessing standing and transfer, was shown to be the most powerful parameter to detect clinical decline compared to D2 and D3 domains\textsuperscript{35}.

Change of D2 domain of motor function under tamoxifen compared to placebo in non-ambulant patients

Since the D1 domain remains around 0% in patients who lost ambulation, it cannot be applied to monitor disease progression or treatment response in this patient group. In contrast, the D2 and D3 domains are more suitable for non-ambulant patients as they assess the retained upper limb functions\textsuperscript{29,32-33}. Particularly the D2 domain was shown to be informative with a decrease of 9.4% per year in non-ambulant patients\textsuperscript{33}. Therefore, the D2 domain, assessing axial and proximal motor function, is defined as the primary endpoint for the group B (non-ambulant) population of the study.

Secondary efficacy outcome measures

Change of motor function measured by the MFM total score, its D2 and D3 domains, NSAA and PUL under tamoxifen compared to placebo

The total MFM and also its D2 and D3 domains are defined as secondary endpoints, giving complete information about all three dimensions of the motor function including axial, proximal and distal motor function. The NSAA is another commonly used and validated test to measure motor function in ambulant children with DMD\textsuperscript{36-37}. The test can be used in children from the age of 4 years\textsuperscript{38}; moreover, a revised version of NSAA was recently proposed to be used in patients above 3 years\textsuperscript{39}. The functional testing of the upper limbs is a reliable parameter both in ambulant and non-ambulant patients, but its application is especially meaningful in patients who have lost ambulation\textsuperscript{40}. 
Change in timed function tests measured by 6MWT, 10MWT and time to rise from the floor under tamoxifen compared to placebo

Timed function tests are useful clinical assessments in ambulant patients since they provide important information about the patient’s endurance. Especially the 6MWT was shown to be a good surrogate marker of disease progression as it independently predicts loss of ambulation\textsuperscript{41-44}. A walking distance of < 350 m in 6MWT is considered as a strong predictor of clinical decline\textsuperscript{41-42, 45-46}. Timed function test of the study will include 6MWT, 10MWT and time to rise from the floor.

Change in quantitative muscle testing measured by grip force under tamoxifen compared to placebo

To measure the change of isometric muscle strength under treatment compared to placebo, quantitative muscle testing using grip force measured by a handheld dynamometer will be performed\textsuperscript{47}.

Change in qMRI measurement of thigh muscles using FF and T2 under tamoxifen compared to placebo

qMRI is considered to be the most sensitive biomarker in patients with DMD. It assesses disease-related tissue changes including fat replacement (muscle FF), muscle edema and inflammation (T2). It objectively correlates with functional outcome measures in detecting clinical decline\textsuperscript{48-51}, reliably shows subclinical changes and can even predict loss of ambulation\textsuperscript{52-53}. In the study, qMRI of all thigh muscles (flexors, extensors, and adductors) will be performed using FF and T2.

Patient reported outcome measures

PARS-III is a parent reported assessment that gives useful information about the psychosocial adjustment of a child. The test has been used in several chronic diseases and described as reliable and valid in patients with DMD\textsuperscript{54}. The PARS-III will be performed throughout the study (at baseline, at weeks 24, 48 and in the OLE phase at weeks 72 and 96).

Safety outcome measures

The following safety assessments are performed at each visit: blood pressure, heart rate, weight, height, Wells score for DVT and ECG. Furthermore, the following safety laboratory assessments will be done by routine testing at each visit: CK, gamma GT, total bilirubin, urea, AP, creatinine, electrolytes, triglycerides and full blood count including erythrocytes, leucocytes (with a differential), platelets, hemoglobin, hematocrit, absolute neutrophil count. Tanner staging, ophthalmological examination, laboratory sexual
hormone concentrations (LH, FSH, testosterone, SHBG), and alpha-fetoprotein will be monitored at baseline, at weeks 24 and 48 and also in the OLE phase at weeks 72 und 96. The cognitive function in the study population will be monitored by means of the RCPM test at baseline, at week 48, and also at week 96 in OLE phase. It is a validated, easy-to-perform, language independent assessment which can be used in patients with severe motor or cognitive impairment. Normative values are available for the patient age group. RCPM has classically been used to measure global cognitive performance and has been used in Duchenne muscular dystrophy\textsuperscript{55}. In selected sites x-ray bone age determination (examination of the left hand) and lumbar spinal bone density using DEXA will be performed at baseline, at week 48, and at week 96 in the OLE phase.

**Further outcomes of interest**

The following markers of tamoxifen metabolism will be assessed: Cyp2D6 and Cyp3A4 are the enzymes involved in the degradation of tamoxifen, while endoxifen and 4-OH-tamoxifen are considered as potential active metabolites. To examine muscle dystrophy biomarkers, TNF, TGF-beta, IL1-β, IL6, platelet-derived growth factor-B (PDGF-B), IGF1, Fibroblast growth factor 21 (FGF-21), connective tissue growth factor (CTGF), osteopontin (OPN), tissue inhibitor of metalloproteinases 1 (TIMP-1), matrix metalloproteinase-2 (MMP-2), and MMP-9 will be analyzed.

**Objectives of the open label extension phase of the main study**

Outcome measures are the same for both the placebo controlled and open label extension phases of the trial. The goal of the OLE part is to test if earlier initiation of tamoxifen treatment (verum arm of the double-blind study) can reduce disease progression more efficiently. Therefore, disease progression during the OLE phase will be compared between both OLE treatment arms. A further aim is to obtain more safety and efficacy information.

**Randomization scheme**

At baseline visit, patients will be randomly assigned either to the active treatment or the control group. Stratification will be performed according to glucocorticoid use into the three strata continuous, intermittent and none glucocorticoid users. The randomization procedure will be implemented by the Clinical Trial Unit (CTU) of the University Hospital Basel into a web-based randomization service tool for multicenter trials (randomizer.at), provided by the Institute for Medical Informatics, Statistics and Documentation of the Medical University Graz. It will include a standard minimization algorithm which will ensure that the treatment groups are balanced within each stratum. To avoid predictable alternation of treatment allocation, and thus potential loss of allocation concealment, patients will be allocated with
a probability of 80 percent to the treatment group to minimize the difference between the groups within the patient's stratum.

**Sample size estimation**

Sample size estimation was performed for the ambulant patients to allow the identification of a significant difference in the D1 domain between the two treatment groups (verum versus placebo). A type-I error rate of $\alpha = 0.05$ was used and the power was set at $1 - \beta = 0.8$. The sample size estimation was based on clinical data of patients in the Placebo-arm of the “Treatment with L-citrulline and metformin in Duchenne muscular dystrophy”-study (DMD02 study)\(^5^2\). The mean change in D1 domain of these patients was 9.1 % during 25 weeks, while previously an annual D1-decline of 17.2 % was reported in ambulant DMD patients\(^3^2\).

A semi parametric method was performed to allow both to account non-parametrically for the available data set and parametrically for the treatment shift. Each sample size, $n_i=1, \ldots, 50 = 30, \ldots, 1500$, was evaluated by drawing 99 times an individual data set of size $n_i$ from the pilot study data set. Here, $n_i$ patients were sampled with replacement from a pilot data set. For each sample, the average disease progression (mean) between baseline and follow-up was estimated. For patients assigned to placebo, the follow-up measurement of the pilot data was used as expected follow-up measurement. In patients assigned to tamoxifen, the follow-up measurement was recalculated by adding the treatment effect. An ANCOVA model was used to assess whether the D1 domain significantly differed between the two treatment groups after 48 weeks when adjusting for baseline values. Based on the assumption that tamoxifen reduces the mean decrease of D1 by 50 % within one year, 79 patients should be screened in group A of the study population. A reduction of 50 % corresponds to an average loss of 4.5 points in the D1 subscore under verum compared to a loss of 9 points under placebo. Assuming a screening failure rate of 10 % and a drop-out rate of 15 %, 79 screened patients would result in 71 randomized patients to ensure 60 evaluable patients in total.

**Statistical analysis**

*Primary analysis*

The primary analysis will be based on the D1 domain of the MFM in ambulant patients. For both groups A and B, two analysis sets will be built. The full analysis set will include all patients who had at least one follow-up measurement at week 24 or later. The per protocol set will include all patients from the full analysis set who had the one year follow-up visit, and who had a drug compliance of 70 - 100 %. The analysis will be done on the intention to treat (ITT) principle. The measurement at randomization (week
0) will be considered as baseline and the measurement at week 48 as primary endpoint. An ANCOVA approach will be used: D1 at 48 weeks will be modeled using a linear regression model including D1 at baseline and treatment groups (verum versus placebo) as predictors in the model. Medication with glucocorticoids will be included as covariable. Since D1 can be performed only in ambulant patients, this patient group will be used for the primary analysis. The model will be controlled by checking the model assumptions and by inspecting the residuals and leverages.

Following sensitivity analysis will be done to support the main analysis: concomitant use of CYP2D6 inhibitors in the treatment arm as interaction term, glucocorticoid use in the treatment arm as interaction term, exclusion of adjustment for glucocorticoid use, exclusion of multiple imputations (the last observation available at least 24 weeks after randomization will be imputed for missing values), inclusion of all measurements at week 0, 12, 24, 36, and 48 in a mixed effects model, repetition of the analysis on the per protocol dataset.

For further efficacy analysis, the previously described ANCOVA approach (based on the primary outcome measure) will be performed also for the OLE phase.

Secondary analyses

The goal of the secondary analyses is to show superiority of tamoxifen compared to placebo in regard to the secondary objectives. The two patient groups will be analyzed in separate models for all endpoints. The analyses will be performed on the full analysis set and include the followings: MFM total score, a subset of D1 domain scores showing more distinct decrease during disease progression in several data sets, D2 domain, D3 domain, NSAA, timed function tests, PUL, QMT, qMRI using muscle FF, and PARS-III. The analyses will use the same statistical model as specified for the main analysis; however, in the calculation of the muscle FF, a beta regression model will be performed.

For safety reasons, an interim analysis is planned after the completion of the double-blind phase of the study. The number and type of treatment-emergent as well as treatment-related adverse events will be summarized and compared between treatment groups. A safety analysis will be performed similarly also for the OLE phase.

Quality control and data protection

The clinical study can only begin in a certain country once approval from all required authorities in that particular country has been received. Any additional requirements imposed by the authorities shall be implemented. The safety of the study will be assured by an independent safety monitoring board organized by the CTU of the University Hospital Basel, Switzerland. It will be composed of independent experts to protect the patient’s safety and will also include Duchenne patient organization.
representatives. An unblinded, independent statistician will be involved. Study monitoring will be performed by the CRO multi-service-monitoring (Maxhüttenstrasse 11, 93055 Regensburg, Germany). The monitor will be responsible for controlling the inclusion and exclusion criteria, all patient data, occurrence of serious adverse events, and drug accountability. The CRO SCRATCH Pharmacovigilance GmbH (Schlossstrasse 25, 35510 Butzbach, Germany) will be responsible for serious adverse event processing and keeping the safety data base.

Direct access to source documents will be permitted for purposes of monitoring, audits and inspections. The investigators of the study will have access to the protocol and the datasets. The statistician will have access to the statistical code during and after the study. A transfer of data will only take place for study purposes and only in encoded form. For inspection purposes, insight to source data will be permitted to the member of the appropriate authorities and also for members of the local ethics committee. During the study, confidentiality will be guaranteed. The principal investigator will guarantee for compliance with national and international data security.

Storage of biological material and related health data

Biological material and related health data will be stored in an encrypted format for follow-up analyses. Blood samples for biomarker analyses will be stored under standardized conditions at each study center until the last patient visit. Then, samples will be sent to the laboratories in Lausanne, Switzerland to perform the planned, batch-wise analyses.

Discussion

DMD is a devastating genetic neuromuscular disorder that affects children from their early years of life. Due to their known anti-inflammatory effects, glucocorticoids have been used since the 1980s as a palliative treatment, and their regular intake has been linked to improved muscle strength, muscle function, and even prolonged ambulation\textsuperscript{55}. Despite their recognizable advantages in DMD, the extensive side effects of long-term corticosteroid use including weight gain and high risk for osteoporosis and diabetes mellitus make this therapy option certainly less attractive in patients at young age. The improved understanding of disease pathophysiological mechanisms led to the initiation of new therapy approaches with the hope of seeing more significant treatment effects combined with better safety. Still, most of the novel therapeutic approaches, as exon skipping therapies or “read through” approaches for mutations are often applicable to a limited number of patients only because of their mutation specific functioning.

Tamoxifen, an estrogen receptor modulator used in estrogen receptor positive breast cancer is a promising agent and seems to have the potential to reduce disease progression in DMD. Based on encouraging preclinical research data conducted in a mouse model of DMD\textsuperscript{21-22}, we aimed to test safety
and efficacy of tamoxifen in patients with DMD. Tamoxifen has already been tested in children having brain tumor, pubertal gynecomastia or short height, and showed good safety and tolerability\textsuperscript{25-28}.

This multicenter, randomized, double-blind and placebo-controlled trial investigates whether tamoxifen can reduce disease progression by at least 50\% compared to placebo in 6.5-12 years old ambulant (group A) DMD patients. The goal of the OLE part is to test if earlier initiation of tamoxifen treatment (patients of the verum arm of the RCT phase of this study) can reduce disease progression more efficiently than later treatment onset. Therefore, disease progression during the OLE phase will be compared between both OLE treatment arms. Finally, we also address the question whether tamoxifen can reduce clinical decline in 10-16 years old non-ambulant DMD patients who are off steroids (group B). The inclusion of these patients was highly encouraged by the European Medicines Agency (EMA) in order to obtain more data on safety and efficacy in this patient group, even if statistical significance is not to be expected. The design of this trial including duration, inclusion and exclusion criteria, efficacy and safety endpoints and statistical analysis regarding sample size and final analysis have been discussed in detail and agreed with external opinions (Committee for Medicinal Products for Human Use (CHMP) of EMA, Advisory Committee for Therapeutics (TACT) of Translational Research in Europe for the Assessment and Treatment of Neuromuscular Disease (TREAT-NMD), Sandoz who is providing the IMP, national competent authorities and responsible ethical committees of the participating countries).

The primary outcome of the study is defined by the motor function measure including evaluation of standing and transfer, axial-, proximal-, and distal motor function. Timed function tests, particularly the 6MWT are commonly used endpoints in clinical trials; however, most of them can only be performed in ambulant patients and show age-dependency due to changes in motor development\textsuperscript{41-42}. According to yet unpublished data of our group, sample sizes showing a longitudinal treatment response of at least 50\% are the lowest if D1 domain of MFM or MFM total score is used compared to timed functions tests including the 6MWT. MFM is commonly used in the field of neuromuscular disorders and is validated in patients with DMD\textsuperscript{21-22}. MFM is not only a sensitive test with a low inter-rater and intra-rater variability, but also meets a highly important criterion of outcome measures, namely the sensitive prediction of clinical decline and loss of ambulation. Total MFM score of 70\% has been described to be predictive for loss of ambulation in one year\textsuperscript{33}; however, in ambulant patients the D1 domain seems to be of higher relevance\textsuperscript{33-34}. D1 domain of 40\% or a mean reduction of yearly 17.2\% has been described to be predictive for loss of ambulation\textsuperscript{33}. Therefore, D1 was chosen to be the primary endpoint for ambulant patients included in the study. In those patients who already lost ambulation and are therefore not able to perform the test, the assessment of axial- and proximal motor function (D2 domain) gives sensitive information about clinical decline\textsuperscript{33}. According to this, the D2 domain will be used as the primary endpoint for the non-ambulant population of the study. Further clinical outcome measures including time function tests, NSAA and QMT will be evaluated as secondary endpoints.

Since none of the clinical tests is completely independent of the evaluator’s skills or the patient’s compliance, the analysis of objective surrogate markers is needed. QMRI is a reliable imaging biomarker
that can detect even subclinical changes in stable or even improved patients\textsuperscript{56-59}. The muscle FF of the thigh was shown to correlate with disease progression, to predict loss of ambulation and to have strong consistency especially with the D1 domain of MFM\textsuperscript{51,56-59}. According to yet unpublished data of our group, when using the FF of the thigh muscles, a sample size of 6 is sufficient to show disease stabilization due to an active treatment over an observation time of 12 months. In comparison, even the most sensitive D1 domain of MFM requires a sample size of 12, and the total MFM score of 72 to see a treatment effect in one year, emphasizing the combination use of both clinical and radiologic outcome measures. Besides efficacy data, also regular safety assessments including vital parameters, laboratory values, ophthalmological examination, and evaluation of cognitive function are included to give useful information about potential risks of the treatment.

Our study not only aims to show safety and efficacy of tamoxifen in children with DMD, but also to gain a better understanding in the mechanism of action of tamoxifen. For this purpose, biomarkers of tamoxifen metabolism and muscle degeneration will be measured throughout the study. The deeper insight into how tamoxifen acts in the muscle might be encouraging to use this drug in a broader spectrum of neuromuscular disorders.

**Trial Status**

Protocol version 8.0 from 8th of April, 2019. Enrolment in this trial started in June 2018 and is expected to be completed with the OLE phase by the end of 2020. The last visit of the last patient is planned to take place in December 2021.

**Abbreviations**

AE: adverse event, AFP: alpha-fetoprotein, ANCOVA: analysis of covariance, AP: alkaline phosphatase, Ca\textsuperscript{2+}: calcium, CK: creatine kinase, CTGF: connective tissue growth factor, CTU: clinical trial unit, DEXA: dual energy X-Ray absorptiometry, DMD: Duchenne muscular dystrophy, ECG: electrocardiogram, ICH-GCP: International Conference on Harmonization-Good Clinical Practice, IGF1: insulin growth factor 1, IL1-\beta: interleukin-1 beta, IL6: interleukin 6, IMP: investigational medicinal product, ITT: intention to treat, FF: muscle fat fraction, FGF-21: fibroblast growth factor 21, FSH: follicle stimulating hormone, K\textsuperscript{+}: potassium, LH: luteinising hormone, MFM: motor function measure, MMP-2: matrix metalloproteinase-2, MMP-9: matrix metalloproteinase-9, Na\textsuperscript{+}: sodium, NSAA: North Star Ambulatory Assessment, OLE: open label extension, PARS-III: Personal-Adjustment and Role Skills-Scale, PUL: proximal upper limb function, PDGF-A: platelet-derived growth factor-A, PDGF-B: platelet-derived growth factor-B, qMRI: quantitative magnetic resonance imaging, OPN: osteopontin, QMT: quantitative muscle testing, RCPM: Raven's Coloured Progressive Matrices, RCT: randomized controlled trial, SAE: serious adverse event, SHBG: sex hormone binding globulin, TAM: tamoxifen, TIMP-1: tissue inhibitor of metalloproteinases 1, TC: telephone call, TNF: tumor necrosis factor, TGF-beta: transforming growth factor beta, 6MWT: 6-minute walk test, 10MWT: 10-meter walk/run test.
Declarations

Ethics approval and consent to participate

The trial was approved by the local ethics committee (Ethics Committee of Both Basel cantons, 2017-01708), the National Swiss Drug Agency (Swissmedic, 2018DR3068) the European Union Drug Regulating Authorities Clinical Trials and (EudraCT 2017-004554-42), the European Union Drug Regulating Authorities Pharmacovigilance (EudraVigilance,) approved the trial. The study was registered at ClinicalTrials.gov (NCT03354039) and at the Swiss National Clinical Trials Portal (SNCTP0000002387) prior recruitment. Patients are being informed about preclinical data, risks and possible benefits of the study. The participation in this study is voluntary. Written informed consent from patients and/or their caregivers is being obtained.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Competing interests

DF is the principle investigator of studies on Spinal Muscular Atrophy sponsored by Hofmann-La Roche Ltd. There are no other activities related to commercial companies. The authors declare that they have no competing interests.

Funding

This project is supported by the Swiss National Science Foundation (SNSF), Scientific and Technological Research Council of Turkey (TÜBİTAK), French National Research Agency (ANF) under the frame of E-Rare-3, the “ERA-Net for Research on Rare Diseases”. Further funding was provided by the Duchenne UK, Duchenne Parent Project Netherlands, and la Association Monegasque contre les myopathies. None of these funding bodies had or will have any influence on the design of the study, the collection, analysis, and interpretation of data or writing the manuscript.
**Authors’ contributions**

SN participated in the design and the conduct of the study and drafted the manuscript. PH participated in the design and the conduct of the study and edited the manuscript. SS1 participated in the design of the trial and edited the manuscript. DRN participated in the organization, design and conduct of the study and edited the manuscript. SS2 performs the statistical analysis, calculated the sample size for the study and edited the manuscript. OB participated in the design and the conduct of the study and edited the manuscript. DF conceived the study, participated in its design, analyses data and drafted the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

DF is supported by the Thomi-Hopf-Foundation, Switzerland.

**References**

1. Theadom A, Rodrigues M, Roxburgh R, Balalla S, Higgins C, Bhattacharjee R, et al. Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology. 2014;43(3-4):259-68.
2. Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79.
3. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2003;2(12):731-40.
4. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002;82(2):291-329.
5. Allen DG, Whitehead NP, Froehner SC. Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. Physiol Rev. 2016;96(1):253-305.
6. Ruegg UT. Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Curr Opin Neurol. 2013;26(5):577-84.
7. Gailly P. New aspects of calcium signaling in skeletal muscle cells: implications in Duchenne muscular dystrophy. Biochim Biophys Acta. 2002;1600(1-2):38-44.
8. Vallejo-Illarramendi A, Toral-Ojeda I, Aldanondo G, López de Munain A. Dysregulation of calcium homeostasis in muscular dystrophies. Expert Rev Mol Med. 2014;16:e16.
9. Bodensteiner JB, Engel AG. Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567,000 muscle fibres in 114 biopsies. Neurology. 1978;28(5):439-46.
10. Jackson MJ, Jones DA, Edwards RH. Measurements of calcium and other elements in muscle biopsy samples from patients with Duchenne muscular dystrophy. Clin Chim Acta. 1985;147(3):215-21.
11. Turner PR, Westwood T, Regen CM, Steinhardt RA. Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature. 1988;335(6192):735-8.

12. Tutdibi O, Brinkmeier H, Rüdel R, Föhr KJ. Increased calcium entry into dystrophin-deficient muscle fibres of MDX and ADR-MDX mice is reduced by ion channel blockers. J Physiol. 1999;515:859-68.

13. Millay DP, Goonasekera SA, Sargent MA, Maillet M, Aronow BJ, Molkentin JD. Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism. Proc Natl Acad Sci U S A. 2009;106(45):19023-8.

14. Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep. 2004;5(9):872-6.

15. Peddi PF. Hormone receptor positive breast cancer: state of the art. Curr Opin Obstet Gynecol. 2018;30(1):51-4.

16. Custódio JB, Dinis TC, Almeida LM, Madeira VM. Tamoxifen and hydroxytamoxifen as intramembraneous inhibitors of lipid peroxidation. Evidence for peroxyl radical scavenging activity. Biochem Pharmacol. 1994;47(11):1989-98.

17. Custodio JB, Moreno AJ, Wallace KB. Tamoxifen inhibits induction of the mitochondrial permeability transition by Ca2+ and inorganic phosphate. Toxicol Appl Pharmacol. 1998;152(1):10-7.

18. Dodds ML, Kargacin ME, Kargacin GJ. Effects of anti-oestrogens and beta-estradiol on calcium uptake by cardiac sarcoplasmic reticulum. Br J Pharmacol. 2001;132(7):1374-82.

19. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-41.

20. Kreher NC, Eugster EA, Shankar RR. The use of tamoxifen to improve height potential in short pubertal boys. Pediatrics. 2005;116:1513–5.

21. Dorchies OM, Reutenauer-Patte J, Dahmane E, Ismail HM, Petermann O, Patthey-Vuadens O, et al. The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy. Am J Pathol. 2013;182(2):485-504.

22. Gayi E, Neff LA, Ismail HM, Ruegg UT, Sca Pozza L, Dorchies OM. Repurposing the Selective Oestrogen Receptor Modulator Tamoxifen for the Treatment of Duchenne Muscular Dystrophy. Chimia (Aarau). 2018;72(4):238-40.

23. Gayi E, Neff LA, Massana Muñoz X, Ismail HM, Sierra M, Mercier T, et al. Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy. Nat Commun. 2018;9(1):4848.

24. Maani N, Sabha N, Rezai K, Ramani A, Groom L, Eltayeb N, et al. Tamoxifen therapy in a murine model of myotubular myopathy. Nat Commun. 2018;9(1):4849.

25. Walter AW, et al. Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital. Pediatr. Hematol. Oncol. 2000;22:247–51.
26. Lawrence SE, Arnold Faught K, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. Pediatr. 2004;145:71–6.

27. de Aquino Gorayeb MM, Aisen S, Nadalin W, Panico Gorayeb R, de Andrade Carvalho H. Treatment of childhood diffuse brain stem tumors: comparison of results in different treatment modalities. Clin Transl Oncol. 2006;8(1):45-9.

28. Skapek SX, et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) Phase II Study. Blood. Cancer. 2013;60:1108–12.

29. Bérard, C, Payan, C, Hodgkinson, I, Fermanian, J, MFM Collaborative Study Group. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005;15(7):463–70.

30. Bérard, C, Vuillerot, C, Girardot, F, Payan, C, and the MFM study group. MFM User’s Manual and score sheet. 2017. http://www.motor-function-measure.org/user-s-manual.aspx. 3rd edition erratum revised and corrected November 2017.

31. Nagy S, Schmidt S, Hafner P, Klein A, Rubino-Nacht D, Gocheva V et al. Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy. J Vis Exp. 2019;(143).

32. Schreiber A, Brochard S, Rippert P, Fontaine-Carbonnel S, Payan C, Poirot I, et al. Group MDC. Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials. Dev Med Child Neurol. 2018;60(2):185-91.

33. Vuillerot C, Girardot F, Payan C, Fermanian J, Iwaz J, De Lattre C, et al. Monitoring changes and predicting loss of ambulation in Duchenne muscular dystrophy with the Motor Function Measure. Dev Med Child Neurol. 2010;52(1):60-5.

34. Vuillerot C, Payan C, Girardot F, Fermanian J, Iwaz J, Bébard C, et al. Group MS. Responsiveness of the motor function measure in neuromuscular diseases. Arch Phys Med Rehabil. 2012;93(12):2251-56.e2251.

35. Bonati U, Hafner P, Schädelin S, Schmid M, Naduvilekoot Devasia A, Schroeder J, et al. Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy. Neuromuscul Disord. 2015;25(9):679-85.

36. Mazzone E, Martinelli D, Berardinelli A, Messina S, D’Amico A, Vasco G et al. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2010;20(11):712-6.

37. Mazzone E, Messina S, Vasco G, Main M, Eagle M, D’Amico A et al. Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord 2009;19(7):458-61.

38. De Sanctis R, Pane M, Sivo S, Ricotti V, Baranello G, Frosini S et al. Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy. Neuromuscul Disord 2015;25(1):14-8.
39. Mercuri E, Coratti G, Messina S, Ricotti V, Baranello G, D’Amico A et al. Revised North Star Ambulatory Assessment for Young Boys with Duchenne Muscular Dystrophy. PLoS One. 2016;11(8):e0160195.

40. Pane M, Mazzone ES, Sivo S, Sormani MP, Messina S, D’Amico A, et al. Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One. 2014;9(10):e108205.

41. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41(4):500-10.

42. McDonald CM, Henricson EK, Abresch RT, Florence JM, Eagle M, Gappmaier E, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve. 2013;48(3):343-56.

43. McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, et al. The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve. 2013;48(3):357-68.

44. Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S, et al. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS One. 2013;8(1):e52512.

45. Pane M, Mazzone ES, Fanelli L, De Sanctis R, Bianco F, Sivo S et al. Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscul Disord. 2014;24(3):201-6.

46. Pane M, Coratti G, Brogna C, Mazzone ES, Mayhew A, Fanelli L et al. Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data. PLoS One. 2018;13(6):e0199223.

47. Hébert LJ, Remec JF, Saulnier J, Vial C, Puymirat J. The use of muscle strength assessed with handheld dynamometers as a non-invasive biological marker in myotonic dystrophy type 1 patients: a multicenter study. BMC Musculoskelet Disord. 2010;11:72.

48. Godi C, Ambrosi A, Nicastro F, Previtali SC, Santarosa C, Napolitano S, et al. Longitudinal MRI quantification of muscle degeneration in Duchenne muscular dystrophy. Ann Clin Transl Neurol. 2016;3(8):607-22.

49. Morrow JM, Sinclair CD, Fischmann A, Machado PM, Reilly MM, Yousry TA, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol. 2016;15(1):65-77.

50. Willcocks RJ, Rooney WD, Triplett WT, Forbes SC, Lott DJ, Senesac CR, et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Ann Neurol. 2016;79(4):535-47.

51. Schmidt S, Hafner P, Klein A, Rubino-Nacht D, Gocheva V, Schroeder J et al. Timed function tests, motor function measure, and quantitative thigh muscle MRI in ambulant children with Duchenne muscular dystrophy: A cross-sectional analysis. Neuromuscul Disord. 2018;28(1):16-23.

52. Hafner P, Bonati U, Rubino D, Gocheva V, Zumbrunn T, Gueven N, Fischer D. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial. Trials. 2016;17(1):389.
53. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2008;(1):CD003725. Update in: Cochrane Database Syst Rev. 2016;(5):CD003725.

54. Hendriksen JG, Poysky JT, Schrans DG, Schouten EG, Aldenkamp AP, Vles JS. Psychosocial adjustment in males with Duchenne muscular dystrophy: psychometric properties and clinical utility of a parent-report questionnaire. J Pediatr Psychol. 2009;34(1):69-78.

55. Wicksell RK, Kihlgren M, Melin L, Eeg-Olofsson O. Specific cognitive deficits are common in children with Duchenne muscular dystrophy. Dev Med Child Neurol. 2004;46(3):154-9.

56. Willcocks RJ, Rooney WD, Triplett WT, Forbes SC, Lott DJ, Senesac CR et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Ann Neurol. 2016;79(4):535-47.

57. Godi C, Ambrosi A, Nicastro F, Previtali SC, Santarosa C, Napolitano S et al. Longitudinal MRI quantification of muscle degeneration in Duchenne muscular dystrophy. Ann Clin Transl Neurol. 2016;3(8):607-22.

58. Fischmann A, Hafner P, Gloor M, Schmid M, Klein A, Pohlman U, et al. Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. J Neurol 2013;260(4):969-74.

59. Bonati U, Hafner P, Schädelin S, Schmid M, Naduvilekoot Devasia A, Schroeder J, et al. Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy. Neuromuscul Disord. 2015;25(9):679-85.

### Tables

**Table 1.**
### Study Periods

| Study Periods | Screening | Baseline | Intervention Period | Follow-up |
|---------------|-----------|----------|---------------------|-----------|
| Week          |           |          | 1                   | TC 2      | 3 | 4 | 5 | 6 |
|               | 0         | 1        | TC                  | 2         | 3 | 4 | 5 | 6 |
|               | -4 (±16 d)| 0        | 6 (±7 d)            | 12 (±16 d)| 24 (±16 d)| 36 (±16 d)| 48 (±16 d)| 60 (±14 d) |

#### Enrolment

- Informed consent
- Demographics
- Medical history
- Inclusion / Exclusion
- Randomization

#### Interventions

- Treatment / Placebo
  - Dispensing of study medication
  - Collection of study medication

#### Assessments

- Adverse events
- Concomitant therapy
- Physical examination¹
- Vital signs²
- Electrocardiogram
- Ophthalmological examination³
- Physiotherapeutic evaluation⁴
- MRI⁵
- Patient reported outcome measures⁶
- Safety lab tests I⁷A
- Safety lab tests II and biomarkers I⁷B
- Biomarkers II⁸
- x-ray bone age determination⁹
- DEXA¹⁰
- Health check via phone
- Wells score for DVT
- Tanner staging
- Raven’s Coloured Progressive Matrices

Table 1. Detailed schedule of the placebo-controlled, double-blind (RCT) phase of TAMMDMD study. ¹General pediatric physical examination, incl. anthropometric measurements (weight, height), ²Blood pressure, heart rate, ³Including visual acuity and slit lamp examination, ⁴Motor function measurement (MFM), North Star Ambulatory Assessment (NSAA), proximal upper limb function, timed function tests including 6-minute walk test (6MWT), 10-minute walk/run test (10MWT), supine up time, quantitative muscle testing (QMT) using Grip force, ⁵Thigh muscle fat fraction (MFF) and T2 time on qMRI, ⁶Personal-Adjustment and Role Skills-Scale (PARS-III),
Chemistry: creatine kinase (CK), gamma GT, total bilirubin, alkaline phosphatase (AP), creatinine, electrolytes (Na⁺, K⁺, Ca²⁺), urea, triglycerides; Hematology: full blood count: erythrocytes, leucocytes (with a differential), platelets, hemoglobin, hematocrit, absolute neutrophil count (ANC). Sexual hormone function (luteinising hormone (LH), follicle stimulating hormone (FSH), testosterone, sex hormone binding globulin (SHBG), alphafetoprotein (AFP), preservation of serum and EDTA full blood to be able to measure plasma levels of tamoxifen (TAM) and its metabolites (endoxifen and 4-OH-tamoxifen) and biomarkers I (connective tissue growth factor (CTGF), fibroblast growth factor 21 (FGF-21), insulin growth factor 1 (IGF1), interleukin-1 beta (IL1-beta), interleukin 6 (IL6), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), osteopontin (OPN), platelet-derived growth factor-A (PDGF-A), platelet-derived growth factor-B (PDGF-B), tissue inhibitor of metalloproteinases 1 (TIMP-1), transforming growth factor beta (TGF-beta), tumor necrosis factor (TNF), Biomarkers II: Cyp2D6, Cyp3A4, In selected sites only, Only for patients not participating in the open label extension phase (OLE).

Table 2.
| Study Periods | Open label treatment | Follow-up |
|---------------|----------------------|-----------|
| Visit         | 1OLE                 | TC        | 2OLE | 3OLE | 4OLE | 5OLE | 6OLE |
| Week          | 48 (±16 d)           | 54 (±7 d) | 60 (±16 d) | 72 (±16 d) | 84 (±16 d) | 96 (±16 d) | 108 (±14 d) |

**Enrolment**
- Informed consent: x
- Inclusion / Exclusion: x

**Interventions**
- Treatment
  - Dispensing of study medication: x
  - Collection of study medication: x

**Assessments**
- Adverse events: x
- Concomitant therapy: x
- Physical examination: x
- Vital signs: x
- Electrocardiogram: x
- Ophthalmological examination: x
- Physiotherapeutic evaluation: x
- MRI: x
- Patient reported outcome measures: x
- Safety lab tests I: x
- Safety lab tests II: x
- x-ray bone age determination: x
- DEXA: x
- Health check via phone: x
- Wells score for DVT: x
- Tanner staging: x
- Raven's Coloured Progressive Matrices: x

**Table 2.** Detailed schedule of the open label extension phase (OLE) of TAMDMD study. ¹General pediatric physical examination, incl. anthropometric measurements (weight, height), ²Blood pressure, heart rate, ³Including visual acuity and slit lamp examination, ⁴Motor function measurement (MFM), North Star Ambulatory Assessment (NSAA), proximal upper limb function, timed function tests including 6-minute walk test (6MWT), 10-minute walk/run test (10MWT), supine up time, quantitative muscle testing (QMT) using Grip force, ⁵Thigh muscle fat fraction (MFF) and T2 time on qMRI, ⁶Personal-Adjustment and Role Skills-Scale (PARS-III), ⁷Chemistry: CK, gamma GT, total bilirubin, alkaline phosphatase, creatinine, electrolytes (Na⁺, K⁺, Ca²⁺), urea, triglycerides; Hematology: full blood count: erythrocytes, leucocytes (with a differential), platelets, hemoglobin, hematocrit, absolute neutrophil count (ANC), ⁸Sexual hormone function (luteinising hormone (LH), follicle
stimulating hormone (FSH), testosterone, sex hormone binding globulin (SHBG), alpha-fetoprotein (AFP). In selected sites only, *Will be assessed at visit 5 (end of study visit).

Figures

Figure 1
Flow chart showing the study design of the placebo-controlled, double-blind (RCT) phase of TAMDMD study.
Figure 2

Flow chart showing the study design of the open label extension phase (OLE).

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- supplement1.doc